银华国证港股通创新药ETF发起式联接C
(023930.jj ) 港股通创新药 (半年) 银华基金管理股份有限公司
基金类型指数型基金(ETF,联接型)成立日期2025-04-18总资产规模6.77亿 (2025-12-31) 基金净值1.2613 (2026-02-12) 基金经理马君管理费用率0.50%管托费用率0.10% (2025-06-30) 成立以来分红再投入年化收益率26.65% (1005 / 5667)
备注 (0): 双击编辑备注
发表讨论

银华国证港股通创新药ETF发起式联接C(023930) - 基金对比

最后更新于:2026-02-12

数据选项
非全收益率指数点位的计算不包含分红再投入,所以理论上指数基金的分红再投入收益率高于其对应的指数点位涨幅。
加载中......
比较起始时间为2026-02-12,最多展示50条数据。
日期银华国证港股通创新药ETF发起式联接C - 相对起始点分红再投入收益率港股通创新药 - 相对起始点收益率
2026-02-1226.65%--
2026-02-1129.30%116.38%
2026-02-1029.14%115.93%
2026-02-0926.07%110.16%
2026-02-0623.86%105.89%
2026-02-0524.13%106.42%
2026-02-0423.82%106.05%
2026-02-0322.94%104.12%
2026-02-0221.38%100.98%
2026-01-3025.76%108.85%
2026-01-2928.87%114.04%
2026-01-2829.96%115.99%
2026-01-2728.01%112.07%
2026-01-2627.21%110.60%
2026-01-2329.42%114.36%
2026-01-2227.72%110.98%
2026-01-2129.66%114.46%
2026-01-2029.59%114.36%
2026-01-1930.56%116.00%
2026-01-1634.59%123.03%
2026-01-1535.04%123.74%
2026-01-1435.71%124.80%
2026-01-1335.71%124.71%
2026-01-1234.34%122.19%
2026-01-0934.19%121.88%
2026-01-0833.72%120.57%
2026-01-0734.10%121.25%
2026-01-0628.76%111.70%
2026-01-0527.82%110.07%
2025-12-3121.38%98.23%
2025-12-3022.83%100.51%
2025-12-2923.56%101.71%
2025-12-2626.03%--
2025-12-2526.07%--
2025-12-2426.21%106.15%
2025-12-2327.07%107.62%
2025-12-2227.02%107.45%
2025-12-1927.92%109.11%
2025-12-1826.24%105.93%
2025-12-1725.60%104.84%
2025-12-1625.18%104.08%
2025-12-1525.98%105.62%
2025-12-1231.48%115.21%
2025-12-1129.57%111.59%
2025-12-1029.99%112.19%
2025-12-0930.87%113.68%
2025-12-0832.56%117.07%
2025-12-0534.99%121.54%
2025-12-0434.84%121.36%
2025-12-0332.39%116.83%